周剂量紫杉类药物联合表阿霉素、环磷酰胺治疗乳腺癌的安全性观察  

A Clinical Study on the Safety of Weekly Paclitaxel /Docetaxel Combined with Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer

作　　者：张倩[1] 黄新恩[1] 唐金海[2] 蔡炜宇[1] 江伟[1] 束永前[3] 

机构地区：[1]江苏省肿瘤医院化疗科 [2]江苏省肿瘤医院普外科,江苏南京210009 [3]江苏省人民医院肿瘤科,江苏南京210000

出　　处：《肿瘤基础与临床》2008年第1期36-38,共3页journal of basic and clinical oncology

基　　金：江苏省人事厅"六大人才高峰"项目(ZK200602);江苏省卫生厅"333高层次人才培养工程";江苏省科技发展计划项目(BS2006006)

摘　　要：目的观察周剂量紫杉类药物联合表阿霉素、环磷酰胺（周剂量TEC/DEC）方案治疗乳腺癌的安全性。方法对19例乳腺癌采用紫杉醇80mg/m^2,d1,8,或多西紫杉醇40mg/m^2,d1,8,静脉滴注;表阿霉素55mg/m^2,d1,2,静脉滴注;环磷酰胺800mg/m^2,d1,静脉推注。每21d为1周期,应用4-6周期,监测毒副反应。结果19例乳腺癌除1例第1周期出现频发室性心动过速,拒绝进一步治疗外,其余毒副反应主要为骨髓抑制（94.7%）、消化道反应（52.6%）、谷丙转氨酶升高（78.9%）,未见过敏反应出现。其毒副反应经扶正、止吐、升白及保肝治疗后,均未影响下一周期治疗。结论周剂量TEC/DEC方案治疗乳腺癌毒副反应易于耐受,安全有效,值得进一步推广应用。Objective To investigate the safety of combination of paclitaxel/docetaxel, epirubicin and cyclophosphamide（TEC/DEC） in the treatment of breast cancer. Methods The 19 patients with breast cancer were treated with paclitaxel 80 mg/m^2 by intravenous infusion for days 1,8, or docetaxe140 mg/m^2 for days 1,8 ; epirubicin 55 mg/m^2 by intravenous infusion for days 1,2 ; cyclophosphamide 800 mg/m^2 for day 1. Every 21 days was a cycle, toxicity was evaluated after each cycles. Results One patient in the 1st cycle had frequently ventricular tachycardia and refused to further treatment, the toxicity of the others was myelosuppression （94. 7% ）, gastrointestinal side-effects （52.6%） , transaminase elevation （78.9%） , no hypersensitivity occurred. Toxicity was tolerable and no treatments were related to death. Conclusions Weekly TEC/DEC is safe, effective, and feasible. Toxicity of this regimen is tolerable and preventable, thus it is deserved to be investigated further in the future.

关 键 词：紫杉醇 多西紫杉醇 表阿霉素 环磷酰胺 乳腺癌 安全性 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]